Topics:

Rheumatology Network

Joint Focus: Spondyloarthritis

For the first time, two societies devoted to spondyloarthropathies have met in joint session. Rheumatology Network was on site to learn the latest from the SPARTAN-GRAPPA conference:
-- Progress toward new PsA criteria ,
-- Impending North American guidelines on spondyloarthropathies, and
-- The growing voice of PsA patients in defining outcomes.

Recent Content

Unpublished results from Phase III trials of the uric acid inhibitor lesinurad offer promise of help for gout patients who have not reached treatment targets with allopurinol or febuxostat.

A large study of veterans reveals factors that predict which people starting methotrexate for rheumatic diseases after the age of 65 will quickly begin to show signs of liver damage.

Being overweight or obese not only increases the risk of rheumatoid arthritis developing in the first place; it also makes RA worse and decreases chances for remission, r

Macrophage activation syndrome, a devastating complication of some rheumatic conditions, shows pathologic similarities to a rare hereditary condition. Genetic studies imply that their similarities may be more than coincidental.

Eliglustat has a better safety profile than the existing approved oral drug for type 1 Gaucher disease, and is easier to take than enzyme replacement therapy.

A new international multicenter study of often-deadly macrophage activation syndrome in systemic JIA reveals key laboratory and clinical warning signs. Watch ferritin levels especially closely.

For psoriasis patients, dermatologists are told, liver biopsy results may be misleading after methotrexate treatment. Noninvasive methods of assessment are no worse, but need improving and standardizing.

By clicking Accept, you agree to become a member of the UBM Medica Community.